细胞周期素依赖性激酶抑制因子与肺癌  

Cyclin dependent kinase inhibitor and lung cancer

作　　者：郭月芳[1] 孙晓琴[2] 

机构地区：[1]上海医药工业研究院药理研究室,上海200437 [2]上海中医药大学实验动物中心,上海201203

出　　处：《世界临床药物》2010年第8期495-499,共5页World Clinical Drug

基　　金：国家"重大新药创制"科技重大专项资助(项目编号2009ZX09301-007)

摘　　要：细胞周期素依赖性激酶抑制因子(CDKI)家族成员中,p16甲基化是肺癌早期诊断的标志之一,P21、P27或P57的高表达与肺癌的治疗预后相关。P16、P21和P27为有效的治疗靶点。目前小分子激动剂及基因治疗方法尚待进一步研究认证。本文综述CDKI(INK4家族和Cip/Kip家族)在肺癌的发生、诊断、治疗和预后等方面的研究进展,以及其作为肺癌治疗靶标的应用价值。In the group of cyclin dependent kinase inhibitors （CDKI） the p16 methylation is one of the biomarkers for early diagnosis of lung cancer,and the over expressions of P21,P27 and P57 are related with its treatment and prognosis. Therefore,P16,P21 and P27 could be used as therapeutic targets of lung cancer. Currently,the researches on small molecule antagonists and gene therapy are in process. This review describes the latest advances on diagnosis,treatment and prognosis of lung cancer through CDKIs,INK4 （inhibitor of CDK4） group and Cip/Kip （CDK-interacting protein/kinase inhibition protein） group,and their applications as therapeutic targets.

关 键 词：细胞周期素依赖性激酶抑制因子 肺癌 基因 诊断 治疗 

分 类 号：R979.1[医药卫生—药品] R734.2[医药卫生—药学]